Citations

Showing 10 of 108152 citations.

Analysis of 90-Day Readmissions After Total Shoulder Arthroplasty
Chung, Andrew S. , Makovicka, Justin L. , Hydrick, Thomas C. , Scott, Kelly, Cho, Samuel , Hattrup, Steven J. , Hydrick, Thomas, Scott, Kelly L, Chung, Andrew

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 24, 2019 | Volume: 7 | Issue: 9 | Pages: No page available

10.1177/2325967119868964 | PMID 31579681 Get It

Background: The number of total shoulder arthroplasty (TSA) procedures performed annually is increasing as a result of an aging population and an increased access to subspecialty-trained upper extremity arthroplasty surgeons. An up-to-date analysis of the incidence of, risk factors for, and reasons for 90-day readmissions in primary anatomic TSA has yet to be performed. Purpose: To characterize 90-day readmissions on a national level. An understanding of these data will help to predict resource utilization and expenses in shoulder arthroplasty. Study Design: Case-control study; Level of evidence, 3. Methods: All adult patients undergoing elective primary TSA in 2014 who were included in the National Readmission Database were included in the analysis. Two cohorts were created according to 90-day readmission status. Multivariable analysis was then performed to determine predictors of 90-day readmissions. Reasons for 30-, 60-, and 90-day readmissions were identified, and total hospital resource utilization was calculated. Results: An estimated 26,023 patients were identified. The 30-, 60-, and 90-day rates of readmissions were 0.6%, 1.2%, and 1.7%, respectively. There was no difference in comorbidity burden between the cohorts. Medicare payer status (odds ratio [OR], 1.63; 95% CI, 1.00-2.65; P = .05), transfer to a skilled nurse facility (OR, 1.50; 95% CI, 1.05-2.14; P = .02), and chronic obstructive pulmonary disease (OR, 1.32; 95% CI, 1.04-1.66; P = .02) were identified as predictors of 90-day readmission. Female sex decreased odds of 90-day readmission (OR, 0.72; 95% CI, 0.59-0.87; P = .001). Ninety-day readmissions were associated with significant cost increases ( P < .001). The most common identifiable reason for related readmissions was a hardware-related complication at all time points. Conclusion: While uncommon, 90-day readmissions after primary TSA are associated with significant patient morbidity and ultimately substantial hospital costs. Truncating readmission analysis at a 30-day period will miss most arthroplasty-related hospital readmissions.
Vertebroplasty appears no better than placebo for painful osteoporotic spinal fractures, and has potential to cause harm
Osborne, Richard H. , Kallmes, David F. , Buchbinder, Rachelle

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 191 | Issue: 9 | Pages: 476-477

10.5694/j.1326-5377.2009.tb02906.x Get It

Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn’s Disease: Are There Differences in the Safety Profiles?
McKenna, Nicholas P. , Alsughayer, Ahmad, Harmsen, William S. , Taparra, Kekoa , Parker, Maile E., Raffals, Laura E. , Loftus, Edward V. , Loftus, Edward V , McKenna, Nicholas P , Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | September 24, 2019 | Volume: 62 | Issue: 11 | Pages: 1352-1362

10.1097/dcr.0000000000001482 | PMID 31567927 Get It

BACKGROUND: The evidence regarding the association of preoperative biologic exposure and postoperative outcomes remains controversial for both antitumor necrosis factor agents and vedolizumab and largely unknown for ustekinumab. OBJECTIVE: The purpose of this study was to determine differences in the rates of 30-day postoperative overall infectious complications and intra-abdominal septic complications among the 3 classes of biologic therapies as compared with no biologic therapy. DESIGN: This was a retrospective review. SETTINGS: The study was conducted at an IBD referral center. PATIENTS: Adult patients with Crohn’s disease who received an antitumor necrosis factor, vedolizumab, ustekinumab, or no biologic therapy within 12 weeks of a major abdominal operation between May 20, 2014, and December 31, 2017, were included. MAIN OUTCOMES MEASURES: Thirty-day overall postoperative infectious complications and intra-abdominal septic complications were measured. RESULTS: A total of 712 patients with Crohn’s disease were included; 272 patients were exposed to an antitumor necrosis factor agents, 127 to vedolizumab, 38 to ustekinumab, and 275 to no biologic therapy within the 12 weeks before an abdominal operation. Patients exposed to a biologic were more likely to be taking a concurrent immunomodulator, but there was no difference in concurrent corticosteroid usage. The particular class of biologic was not independently associated with total overall infectious complications. Vedolizumab was associated with an increased rate of intra-abdominal sepsis on univariate analysis but not on multivariable analysis. Combination immunosuppression was associated with both an increased rate of overall postoperative infectious complications and intra-abdominal sepsis. LIMITATIONS: The study was limited by its retrospective design and single-center data. CONCLUSIONS: The overall rate of total infectious complications or intra-abdominal septic complications was not increased based on preoperative exposure to a particular class of biologic. Rates increased with combination immunosuppression of biologic therapy with corticosteroids and previous abdominal resection. See Video Abstract at http://links.lww.com/DCR/B24. BIOLÓGICOS Y COMPLICACIONES POSTOPERATORIAS DE 30 DÍAS DESPUÉS DE LAS OPERACIONES ABDOMINALES PARA LA ENFERMEDAD DE CROHN: ¿EXISTEN DIFERENCIAS EN LOS PERFILES DE SEGURIDAD?: ANTECEDENTES: La evidencia sobre la asociación de la exposición biológica preoperatoria y los resultados postoperatorios sigue siendo controvertida controversial tanto para los agentes del factor de necrosis tumoral (anti-TNF) como para el vedolizumab, y en gran parte desconocida para el ustekinumab. OBJETIVO: Determinar las diferencias en las tasas de complicaciones infecciosas generales postoperatorias de 30 días y complicaciones sépticas intraabdominales entre las tres clases de terapias biológicas en comparación con ninguna terapia biológica. DISEÑO: Revisión retrospectiva. AMBIENTE: centro de referencia de la enfermedad inflamatoria intestinal. PACIENTES: Pacientes adultos con enfermedad de Crohn que recibieron un factor de necrosis antitumoral, vedolizumab, ustekinumab o ningún tratamiento biológico dentro de las 12 semanas de una operación abdominal mayor entre el 5/20/2014 y el 12/31/2017. PRINCIPALES MEDIDAS DE RESULTADOS: Complicaciones infecciosas postoperatorias generales de 30 días, complicaciones sépticas intraabdominales. RESULTADOS: Se incluyeron setecientos doce pacientes con enfermedad de Crohn; 272 pacientes fueron expuestos a un anti-TNF, 127 a vedolizumab, 38 a ustekinumab y 275 a ninguna terapia biológica dentro de las 12 semanas previas a una operación abdominal. Los pacientes expuestos a un producto biológico tenían más probabilidades de tomar un inmunomodulador concurrente, pero no hubo diferencias en el uso simultáneo de corticosteroides. La clase particular de productos biológicos no se asoció de forma independiente con las complicaciones infecciosas totales. Vedolizumab se asoció con una mayor tasa de sepsis intraabdominal en el análisis univariable, pero no en el análisis multivariable. La inmunosupresión combinada se asoció tanto con una mayor tasa de complicaciones infecciosas postoperatorias generales como con sepsis intraabdominal. LIMITACIONES: Diseño retrospectivo, datos de centro único. CONCLUSIONES: La tasa general de complicaciones infecciosas totales o complicaciones sépticas intraabdominales no aumentó en función de la exposición preoperatoria a una clase particular de productos biológicos. Las tasas aumentaron con la combinación de inmunosupresión de la terapia biológica con corticosteroides y resección abdominal previa. Vea el Resumen del Video en http://links.lww.com/DCR/B24.
Easy EMG: A Guide to Performing Nerve Conduction Studies and Electromyography, Second Edition
Ross, Mark A.

Mayo Clinic

Journal of Clinical Neurophysiology | September 24, 2019 | Volume: 37 | Issue: 5 | Pages: 465-465

10.1097/wnp.0000000000000586 Get It

Vertebroplasty appears no better than placebo for painful osteoporotic spinal fractures, and has potential to cause harm
Kallmes, David F. , Buchbinder, Rachelle , Osborne, Richard H.

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 192 | Issue: 3 | Pages: 174-175

10.5694/j.1326-5377.2010.tb03467.x | PMID 19883338 Get It

Non‐ulcer dyspepsia and Campylobacter pylori gastritis: to treat or not to treat?
Talley, Nicholas J.

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 147 | Issue: 9 | Pages: 471-471

10.5694/j.1326-5377.1987.tb133630.x Get It

Invited editorial presents an accurate summary of the results of two randomised placebo‐controlled trials of vertebroplasty
Osborne, Richard H. , Kallmes, David F. , Buchbinder, Rachelle

Mayo Clinic

Medical Journal of Australia | September 24, 2019 | Volume: 192 | Issue: 6 | Pages: 338-341

10.5694/j.1326-5377.2010.tb03534.x | PMID 20230352 Get It

Contrast enhanced ultrasound characterization of surgically resected renal masses in patients on dialysis
Kahn, Amanda E. , Ostrowski, A., Caserta, Melanie P. , Galler, Isabella, Thiel, David D. , Ostrowski, Andrew K, Galler, Isabella J, Kahn, Amanda

Mayo Clinic

Scandinavian Journal of Urology | September 24, 2019 | Volume: 53 | Issue: 5 | Pages: 344-349

10.1080/21681805.2019.1666917 | PMID 31549563 Get It

Post-surgical hydropneumopericardium: a case report of dramatic increase in the apparent size of pericardial effusion with positional changes
Ali, Yehia Z , Aung, Htin , Doll, Nathan J, Aung, Htin, Pislaru, Sorin V.

Mayo Clinic

European Heart Journal - Case Reports | September 24, 2019 | Volume: 3 | Issue: 4 | Pages: 1-4

10.1093/ehjcr/ytz160 | PMID 31911990 Get It

Abstract Background Pneumopericardium is an uncommon clinical finding. It most commonly occurs after chest trauma but can also emerge as a complication following interventional or surgical procedures and can result in life-threatening complications. A high index of clinical suspicion should be present and once the condition is recognized, it should be managed promptly. Paucity of literature on pneumopericardium makes outlining any new case of paramount importance to emphasize the aspects of diagnosis and management of this rare condition. Case summary A 59-year-old woman with severe mitral valve and moderate tricuspid valve regurgitation underwent mitral and tricuspid valve repair with uneventful post-operative in-hospital stay. She presented 10 days after discharge with progressive shortness of breath. Chest X-ray revealed right hydropneumothorax. Transthoracic echocardiography (TTE) performed in the emergency department showed an apparently small pericardial effusion with patient in supine position; the effusion size increased substantially when imaging in left lateral decubitus, with presence of intrapericardial air bubbles. Computed tomography scan of the chest confirmed the presence of right hydropneumothorax and hydropneumopericardium, with a communicating pleuro-pericardial tract. The patient underwent chest tube placement which successfully decompressed both pleural and pericardial space. Discussion Hydropneumopericardium is a rare post-operative complication. Comprehensive TTE with imaging from multiple acoustic windows is mandatory when evaluating the extent of pericardial effusion. Presence of cardiac tamponade is crucial in determining the management plan.